PDS Biotechnology Corporation (FRA:EU6)

Market Cap	41.57M
Revenue (ttm)	n/a
Net Income (ttm)	-29.73M
Shares Out	n/a
EPS (ttm)	-0.69
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,784
Average Volume	389
Open	0.7665
Previous Close	0.8270
Day's Range	0.7665 - 0.7665
52-Week Range	0.6085 - 1.8370
Beta	n/a
RSI	47.92
Earnings Date	Mar 26, 2026

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company’s lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protei...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Employees: 24
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EU6

Financial Performance

Financial numbers in USD